Biocartis

  • Accelerated bookbuild offering amounting to €32.7m.
  • Proceeds will be used to finance further clinical trials, to support the global roll-out of its products and to fund the expansion of manufacturing capacity. 
  • Kempen & Co acted as Joint Bookrunner in the transaction.